Skip to main content
Top
Published in: Current Cardiology Reports 3/2012

01-06-2012 | Congestive Heart Failure (J Lindenfeld, Section Editor)

The Comorbidity Conundrum: A Focus on the Role of Noncardiovascular Chronic Conditions in the Heart Failure Patient

Authors: Robert Lee Page II, JoAnn Lindenfeld

Published in: Current Cardiology Reports | Issue 3/2012

Login to get access

Abstract

The rapid aging of the US population combined with improvements in modern medicine has created a new public health concern of comorbidity, a chronic condition that co-exists with a primary illness. Over 141 million Americans suffer from one or more comorbid conditions. In the heart failure (HF) patient, this comorbidity burden is particularly high, with over 40% of patients having five or more chronic conditions. These comorbidities can vary from being a risk factor to a cause of HF progression or even a precipitating factor for decompensation. Comorbidities, particularly the noncardiovascular conditions, have been associated with greater health resource utilization, poor health outcomes, and increased mortality. To minimize the negative impact that these comorbidities have on patient outcomes, appropriate attention should be paid to identifying, prioritizing, and managing each condition; minimizing medication complexity and polypharmacy; and improving overall coordination of care between providers and patients.
Literature
2.
go back to reference Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep. 2004;119:263–70.PubMedCrossRef Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep. 2004;119:263–70.PubMedCrossRef
3.
go back to reference Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269–76.PubMedCrossRef Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269–76.PubMedCrossRef
4.
go back to reference Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc. 2009;57:225–30.PubMedCrossRef Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc. 2009;57:225–30.PubMedCrossRef
5.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209.PubMedCrossRef Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209.PubMedCrossRef
6.
go back to reference •• Metra M, Zaca V, Parati G, et al. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown). 2011;12:76–84. Published on behalf of the Heart Failure Study Group of the Italian Society of Cardiology, this is the most comprehensive review of the epidemiological, pathophysiological, and clinical characteristics of comorbidities as they impact HF treatment..CrossRef •• Metra M, Zaca V, Parati G, et al. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown). 2011;12:76–84. Published on behalf of the Heart Failure Study Group of the Italian Society of Cardiology, this is the most comprehensive review of the epidemiological, pathophysiological, and clinical characteristics of comorbidities as they impact HF treatment..CrossRef
7.
8.
go back to reference Brunner-La Rocca HP, Buser PT, Schindler R, et al. Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J. 2006;151:949–55.PubMedCrossRef Brunner-La Rocca HP, Buser PT, Schindler R, et al. Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J. 2006;151:949–55.PubMedCrossRef
9.
10.
go back to reference •• Ahluwalia SC, Gross CP, Chaudhry SI, et al. Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med. 2011;26:1145–51. Using Medicare beneficiaries, this is the first study to evaluate the impact of age on comorbidity burden..PubMedCrossRef •• Ahluwalia SC, Gross CP, Chaudhry SI, et al. Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med. 2011;26:1145–51. Using Medicare beneficiaries, this is the first study to evaluate the impact of age on comorbidity burden..PubMedCrossRef
11.
go back to reference •• Ahluwalia SC, Gross CP, Chaudhry SI, et al. Impact of comorbidity on mortality among older persons with advanced heart failure. J Gen Intern Med. 2011. Available at: http://www.springerlink.com/content/u838377v8wg07031/fulltext.pdf. Accessed December 2011. Using Medicare beneficiaries, these data provide the impact that comorbidities have on mortality in both hospitalized and nonhospitalized patients with HF. •• Ahluwalia SC, Gross CP, Chaudhry SI, et al. Impact of comorbidity on mortality among older persons with advanced heart failure. J Gen Intern Med. 2011. Available at: http://​www.​springerlink.​com/​content/​u838377v8wg07031​/​fulltext.​pdf. Accessed December 2011. Using Medicare beneficiaries, these data provide the impact that comorbidities have on mortality in both hospitalized and nonhospitalized patients with HF.
12.
go back to reference Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.PubMedCrossRef Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.PubMedCrossRef
13.
go back to reference • Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136–43. Using NHANES data, these data describe the increase in comorbidity and medication burden over the past two decades in patients with HF..PubMedCrossRef • Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136–43. Using NHANES data, these data describe the increase in comorbidity and medication burden over the past two decades in patients with HF..PubMedCrossRef
14.
go back to reference Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood). 2001;20:233–41.CrossRef Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood). 2001;20:233–41.CrossRef
15.
go back to reference Lee DS, Donovan L, Austin PC, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182–8.PubMedCrossRef Lee DS, Donovan L, Austin PC, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182–8.PubMedCrossRef
16.
go back to reference Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82.PubMedCrossRef Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82.PubMedCrossRef
17.
go back to reference Page 2nd RL, Strongin K, Millis R, Hogan C, Lindenfeld J. Medicare beneficiaries with mild to severe heart failure See 15–23 different providers annually. Circulation. 2008;118:S_1030. Page 2nd RL, Strongin K, Millis R, Hogan C, Lindenfeld J. Medicare beneficiaries with mild to severe heart failure See 15–23 different providers annually. Circulation. 2008;118:S_1030.
18.
go back to reference Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med. 2005;165:2069–76.PubMedCrossRef Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med. 2005;165:2069–76.PubMedCrossRef
19.
go back to reference Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.PubMedCrossRef Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.PubMedCrossRef
20.
go back to reference Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516–20.PubMedCrossRef Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516–20.PubMedCrossRef
21.
go back to reference Page RL 2nd, Strongin K, Millis R, Hogan C, Lindenfeld J. The magnitude of health care resource utilization by Medicare beneficiaries with heart failure. Circulation. 2007;116:II-600. Page RL 2nd, Strongin K, Millis R, Hogan C, Lindenfeld J. The magnitude of health care resource utilization by Medicare beneficiaries with heart failure. Circulation. 2007;116:II-600.
22.
go back to reference Zhang JX, Rathouz PJ, Chin MH. Comorbidity and the concentration of healthcare expenditures in older patients with heart failure. J Am Geriatr Soc. 2003;51(4):476–82.PubMedCrossRef Zhang JX, Rathouz PJ, Chin MH. Comorbidity and the concentration of healthcare expenditures in older patients with heart failure. J Am Geriatr Soc. 2003;51(4):476–82.PubMedCrossRef
23.
go back to reference Oudejans I, Mosterd A, Zuithoff NP, Hoes AW. Comorbidity drives mortality in newly diagnosed heart failure: a study among geriatric outpatients. J Card Fail. 2012;18:47–52.PubMedCrossRef Oudejans I, Mosterd A, Zuithoff NP, Hoes AW. Comorbidity drives mortality in newly diagnosed heart failure: a study among geriatric outpatients. J Card Fail. 2012;18:47–52.PubMedCrossRef
24.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef
25.
go back to reference Clarke B, Howlett J, Sapp J, et al. The effect of comorbidity on the competing risk of sudden and nonsudden death in an ambulatory heart failure population. Can J Cardiol. 2011;27:254–61.PubMedCrossRef Clarke B, Howlett J, Sapp J, et al. The effect of comorbidity on the competing risk of sudden and nonsudden death in an ambulatory heart failure population. Can J Cardiol. 2011;27:254–61.PubMedCrossRef
26.
go back to reference Chaudhry SI, Wang Y, Gill TM, Krumholz HM. Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol. 2010;55:309–16.PubMedCrossRef Chaudhry SI, Wang Y, Gill TM, Krumholz HM. Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol. 2010;55:309–16.PubMedCrossRef
27.
go back to reference Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008;51:93–102.PubMedCrossRef Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008;51:93–102.PubMedCrossRef
28.
go back to reference Page 2nd RL, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy. 2003;23:945–54.PubMedCrossRef Page 2nd RL, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy. 2003;23:945–54.PubMedCrossRef
29.
go back to reference • Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol. 2010;61:509–21. This review describes in detail the relationship between the similarities in HF pathophysiology and development of central nervous system disorders..PubMed • Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol. 2010;61:509–21. This review describes in detail the relationship between the similarities in HF pathophysiology and development of central nervous system disorders..PubMed
30.
go back to reference Dec GW. Anemia in heart failure time to rethink its etiology and treatment? J Am Coll Cardiol. 2006;48:2490–2.PubMedCrossRef Dec GW. Anemia in heart failure time to rethink its etiology and treatment? J Am Coll Cardiol. 2006;48:2490–2.PubMedCrossRef
31.
go back to reference Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998;92:1321–5.PubMedCrossRef Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998;92:1321–5.PubMedCrossRef
32.
go back to reference Agostoni P, Cattadori G, Guazzi M, Palermo P, Bussotti M, Marenzi G. Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. Am Heart J. 2000;140:e24.PubMedCrossRef Agostoni P, Cattadori G, Guazzi M, Palermo P, Bussotti M, Marenzi G. Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. Am Heart J. 2000;140:e24.PubMedCrossRef
33.
go back to reference Jefferson AL. Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis. 2010;20:813–21.PubMed Jefferson AL. Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis. 2010;20:813–21.PubMed
34.
go back to reference Qiu C, Winblad B, Marengoni A, et al. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006;166:1003–8.PubMedCrossRef Qiu C, Winblad B, Marengoni A, et al. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006;166:1003–8.PubMedCrossRef
35.
go back to reference Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358–64.PubMedCrossRef Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358–64.PubMedCrossRef
36.
37.
go back to reference Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol. 2006;26:296–306.PubMedCrossRef Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol. 2006;26:296–306.PubMedCrossRef
38.
go back to reference Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305–11.PubMedCrossRef Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305–11.PubMedCrossRef
39.
go back to reference Ukena C, Mahfoud F, Kindermann M, et al. The cardiopulmonary continuum systemic inflammation as ‘common soil’ of heart and lung disease. Int J Cardiol. 2010;145:172–6.PubMedCrossRef Ukena C, Mahfoud F, Kindermann M, et al. The cardiopulmonary continuum systemic inflammation as ‘common soil’ of heart and lung disease. Int J Cardiol. 2010;145:172–6.PubMedCrossRef
40.
42.
go back to reference Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.PubMedCrossRef Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.PubMedCrossRef
43.
go back to reference Faulx MD, Francis GS. Adverse drug reactions in patients with cardiovascular disease. Curr Probl Cardiol. 2008;33:703–68.PubMedCrossRef Faulx MD, Francis GS. Adverse drug reactions in patients with cardiovascular disease. Curr Probl Cardiol. 2008;33:703–68.PubMedCrossRef
44.
46.
go back to reference van Diepen S, Majumdar SR, Bakal JA, et al. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation. 2008;118:1946–52.PubMedCrossRef van Diepen S, Majumdar SR, Bakal JA, et al. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation. 2008;118:1946–52.PubMedCrossRef
47.
go back to reference Rich MW. Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Cardiol. 2005;14:134–41.PubMedCrossRef Rich MW. Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Cardiol. 2005;14:134–41.PubMedCrossRef
48.
go back to reference Jugdutt BI. Aging and heart failure: changing demographics and implications for therapy in the elderly. Heart Fail Rev. 2010;15:401–5.PubMedCrossRef Jugdutt BI. Aging and heart failure: changing demographics and implications for therapy in the elderly. Heart Fail Rev. 2010;15:401–5.PubMedCrossRef
49.
go back to reference Mascarenhas J, Azevedo A, Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Curr Opin Pulm Med. 2010;16:106–11.PubMedCrossRef Mascarenhas J, Azevedo A, Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Curr Opin Pulm Med. 2010;16:106–11.PubMedCrossRef
50.
go back to reference Mascarenhas J, Lourenco P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155:521–5.PubMedCrossRef Mascarenhas J, Lourenco P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155:521–5.PubMedCrossRef
51.
go back to reference Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Heart failure and COPD: partners in crime? Respirology. 2010;15:895–901.PubMedCrossRef Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Heart failure and COPD: partners in crime? Respirology. 2010;15:895–901.PubMedCrossRef
52.
go back to reference Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70.PubMedCrossRef Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70.PubMedCrossRef
53.
go back to reference Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–9.PubMedCrossRef Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–9.PubMedCrossRef
54.
go back to reference Staszewsky L, Wong M, Masson S, et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007;13:797–804.PubMedCrossRef Staszewsky L, Wong M, Masson S, et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007;13:797–804.PubMedCrossRef
55.
go back to reference De Blois J, Simard S, Atar D, Agewall S. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail. 2010;16:225–9.PubMedCrossRef De Blois J, Simard S, Atar D, Agewall S. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail. 2010;16:225–9.PubMedCrossRef
56.
go back to reference Boudestein LC, Rutten FH, Cramer MJ, et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11:1182–8.PubMedCrossRef Boudestein LC, Rutten FH, Cramer MJ, et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11:1182–8.PubMedCrossRef
57.
go back to reference Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49:171–80.PubMedCrossRef Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49:171–80.PubMedCrossRef
58.
go back to reference Abroug F, Ouanes-Besbes L. Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide. Curr Opin Crit Care. 2008;14:340–7.PubMedCrossRef Abroug F, Ouanes-Besbes L. Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide. Curr Opin Crit Care. 2008;14:340–7.PubMedCrossRef
59.
go back to reference Tung RH, Camargo Jr CA, Krauser D, et al. Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med. 2006;48:66–74.PubMedCrossRef Tung RH, Camargo Jr CA, Krauser D, et al. Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med. 2006;48:66–74.PubMedCrossRef
60.
go back to reference de Groote P, Isnard R, Clerson P, et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. Eur J Heart Fail. 2009;11:85–91.PubMedCrossRef de Groote P, Isnard R, Clerson P, et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. Eur J Heart Fail. 2009;11:85–91.PubMedCrossRef
61.
go back to reference Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016.PubMedCrossRef Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016.PubMedCrossRef
62.
go back to reference Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–e194.PubMedCrossRef Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–e194.PubMedCrossRef
63.
go back to reference Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.PubMedCrossRef Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.PubMedCrossRef
64.
go back to reference van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818–24.PubMedCrossRef van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818–24.PubMedCrossRef
65.
go back to reference • Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11:684–90. This is one of the more robust studies evaluating bisoprolol in patients with underlying COPD..PubMedCrossRef • Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11:684–90. This is one of the more robust studies evaluating bisoprolol in patients with underlying COPD..PubMedCrossRef
66.
go back to reference •• Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of β-blockers and β-agonists. J Am Coll Cardiol. 2011;57:2127–38. This systematic review of the literature and guidelines specifically address the use the β blockers and β agonists, providing specific recommendations for HF patients..PubMedCrossRef •• Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of β-blockers and β-agonists. J Am Coll Cardiol. 2011;57:2127–38. This systematic review of the literature and guidelines specifically address the use the β blockers and β agonists, providing specific recommendations for HF patients..PubMedCrossRef
67.
go back to reference • Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780–7. This is the a randomized, open-label triple crossover trial that demonstrates switching between β 1 -selective β blockers and the nonselective β-blocker carvedilol is well tolerated but results in demonstrable changes in airway function in patients with COPD and HF..PubMedCrossRef • Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780–7. This is the a randomized, open-label triple crossover trial that demonstrates switching between β 1 -selective β blockers and the nonselective β-blocker carvedilol is well tolerated but results in demonstrable changes in airway function in patients with COPD and HF..PubMedCrossRef
68.
go back to reference Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.PubMedCrossRef Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.PubMedCrossRef
69.
go back to reference Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001;161:1725–30.PubMedCrossRef Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001;161:1725–30.PubMedCrossRef
70.
go back to reference Jaarsma T, Johansson P, Agren S, Stromberg A. Quality of life and symptoms of depression in advanced heart failure patients and their partners. Curr Opin Support Palliat Care. 2011;4:233–7.CrossRef Jaarsma T, Johansson P, Agren S, Stromberg A. Quality of life and symptoms of depression in advanced heart failure patients and their partners. Curr Opin Support Palliat Care. 2011;4:233–7.CrossRef
71.
go back to reference Johansson P, Nieuwenhuis M, Lesman-Leegte I, et al. Depression and the delay between symptom onset and hospitalization in heart failure patients. Eur J Heart Fail. 2011;13:214–9.PubMedCrossRef Johansson P, Nieuwenhuis M, Lesman-Leegte I, et al. Depression and the delay between symptom onset and hospitalization in heart failure patients. Eur J Heart Fail. 2011;13:214–9.PubMedCrossRef
72.
go back to reference Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.PubMedCrossRef Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.PubMedCrossRef
73.
go back to reference Murberg TA, Furze G. Depressive symptoms and mortality in patients with congestive heart failure: a six-year follow-up study. Med Sci Monit. 2004;10:CR643–8.PubMed Murberg TA, Furze G. Depressive symptoms and mortality in patients with congestive heart failure: a six-year follow-up study. Med Sci Monit. 2004;10:CR643–8.PubMed
74.
go back to reference O’Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med. 2008;168:2232–7.PubMedCrossRef O’Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med. 2008;168:2232–7.PubMedCrossRef
75.
go back to reference Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med. 2007;167:367–73.PubMedCrossRef Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med. 2007;167:367–73.PubMedCrossRef
76.
go back to reference Wu JR, Moser DK, De Jong MJ, et al. Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J. 2009;157:285–91.PubMedCrossRef Wu JR, Moser DK, De Jong MJ, et al. Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J. 2009;157:285–91.PubMedCrossRef
77.
go back to reference Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366:2005–11.PubMedCrossRef Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366:2005–11.PubMedCrossRef
78.
go back to reference Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Fail Clin. 2011;7:11–21.PubMedCrossRef Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Fail Clin. 2011;7:11–21.PubMedCrossRef
79.
go back to reference Sherwood A, Blumenthal JA, Hinderliter AL, et al. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. J Am Coll Cardiol. 2011;57:418–23.PubMedCrossRef Sherwood A, Blumenthal JA, Hinderliter AL, et al. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. J Am Coll Cardiol. 2011;57:418–23.PubMedCrossRef
80.
go back to reference Tousoulis D, Antonopoulos AS, Antoniades C, et al. Role of depression in heart failure–choosing the right antidepressive treatment. Int J Cardiol. 2010;140:12–8.PubMedCrossRef Tousoulis D, Antonopoulos AS, Antoniades C, et al. Role of depression in heart failure–choosing the right antidepressive treatment. Int J Cardiol. 2010;140:12–8.PubMedCrossRef
81.
go back to reference •• O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56:692–9. This is the first large, randomized placebo-controlled trial evaluating the impact of sertraline on both depression scores and cardiovascular events in patients with depression and HF..PubMedCrossRef •• O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56:692–9. This is the first large, randomized placebo-controlled trial evaluating the impact of sertraline on both depression scores and cardiovascular events in patients with depression and HF..PubMedCrossRef
82.
go back to reference • Jiang W, Krishnan R, Kuchibhatla M, et al. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol. 2011;107:545–51. This is a subanalysis of the SADHART-CHF study showing that remission from depression may improve the cardiovascular outcomes in patients with HF..PubMedCrossRef • Jiang W, Krishnan R, Kuchibhatla M, et al. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol. 2011;107:545–51. This is a subanalysis of the SADHART-CHF study showing that remission from depression may improve the cardiovascular outcomes in patients with HF..PubMedCrossRef
83.
go back to reference Angermann CE, Gelbrich G, Stork S, et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail. 2007;9:1212–22.PubMedCrossRef Angermann CE, Gelbrich G, Stork S, et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail. 2007;9:1212–22.PubMedCrossRef
84.
go back to reference Edelmann F, Stahrenberg R, Gelbrich G, et al. Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol. 2011;100:755–64.PubMedCrossRef Edelmann F, Stahrenberg R, Gelbrich G, et al. Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol. 2011;100:755–64.PubMedCrossRef
Metadata
Title
The Comorbidity Conundrum: A Focus on the Role of Noncardiovascular Chronic Conditions in the Heart Failure Patient
Authors
Robert Lee Page II
JoAnn Lindenfeld
Publication date
01-06-2012
Publisher
Current Science Inc.
Published in
Current Cardiology Reports / Issue 3/2012
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-012-0259-9

Other articles of this Issue 3/2012

Current Cardiology Reports 3/2012 Go to the issue

Congestive Heart Failure (J Lindenfeld, Section Editor)

Role of Antithrombotic Agents in Heart Failure

Congestive Heart Failure (J Lindenfeld, Section Editor)

Isolated Ultrafiltration in Heart Failure Patients

Echocardiography (RM Lang, Section Editor)

Aortic Atherosclerosis and Embolic Events

Echocardiography (RM Lang, Section Editor)

Left Atrial Volume: Clinical Value Revisited